Telomir Pharmaceuticals (TELO) Competitors $3.91 -0.27 (-6.46%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.94 +0.03 (+0.90%) As of 02/21/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TELO vs. MLYS, TRDA, RNAC, HUMA, ARCT, SNDL, KALV, PROK, ABVX, and PGENShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), Humacyte (HUMA), Arcturus Therapeutics (ARCT), SNDL (SNDL), KalVista Pharmaceuticals (KALV), ProKidney (PROK), ABIVAX Société Anonyme (ABVX), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Mineralys Therapeutics Entrada Therapeutics Cartesian Therapeutics Humacyte Arcturus Therapeutics SNDL KalVista Pharmaceuticals ProKidney ABIVAX Société Anonyme Precigen Telomir Pharmaceuticals (NASDAQ:TELO) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Do analysts prefer TELO or MLYS? Telomir Pharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 283.63%. Mineralys Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 182.43%. Given Telomir Pharmaceuticals' higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TELO or MLYS? In the previous week, Telomir Pharmaceuticals and Telomir Pharmaceuticals both had 1 articles in the media. Mineralys Therapeutics' average media sentiment score of 0.34 beat Telomir Pharmaceuticals' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Telomir Pharmaceuticals Neutral Mineralys Therapeutics Neutral Which has preferable valuation and earnings, TELO or MLYS? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.58-6.74Mineralys TherapeuticsN/AN/A-$177.81M-$3.64-2.63 Is TELO or MLYS more profitable? Mineralys Therapeutics' return on equity of -67.97% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,170.58% -832.67% Mineralys Therapeutics N/A -67.97%-62.40% Do institutionals and insiders believe in TELO or MLYS? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer TELO or MLYS? Mineralys Therapeutics received 15 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformTelomir PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesMineralys TherapeuticsOutperform Votes16100.00% Underperform VotesNo Votes SummaryMineralys Therapeutics beats Telomir Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.37M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-6.746.1326.4618.82Price / SalesN/A313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book195.506.747.634.64Net Income-$16.53M$138.11M$3.18B$245.69M7 Day Performance-8.86%-2.02%-1.82%-2.63%1 Month Performance-20.69%-1.54%0.22%-2.37%1 Year Performance-54.85%-3.14%17.49%13.65% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.2926 of 5 stars$3.91-6.5%$15.00+283.6%-54.8%$124.41MN/A0.001Analyst ForecastNews CoverageMLYSMineralys Therapeutics2.6396 of 5 stars$10.24+0.4%$27.00+163.7%-37.3%$509.65MN/A-3.1328TRDAEntrada Therapeutics3.3167 of 5 stars$13.44+6.4%$25.67+91.0%-2.0%$502.93M$215.23M8.45110Positive NewsRNACCartesian Therapeutics1.7124 of 5 stars$19.67+3.4%$42.86+117.9%-11.1%$500.01M$26M-0.3764HUMAHumacyte3.1294 of 5 stars$3.91-0.3%$13.71+250.7%-16.4%$492.11M$1.57M-2.92150Short Interest ↓ARCTArcturus Therapeutics2.6171 of 5 stars$18.05+10.0%$65.00+260.1%-49.6%$488.97M$169.93M-8.13180Gap UpHigh Trading VolumeSNDLSNDL3.5196 of 5 stars$1.86flat$3.25+74.7%+28.3%$488.77M$673.33M-6.002,516KALVKalVista Pharmaceuticals4.6917 of 5 stars$9.76+2.4%$23.80+143.9%-23.1%$482.34MN/A-2.68100Short Interest ↓News CoveragePROKProKidney1.3528 of 5 stars$1.61+0.6%$4.50+179.5%-1.3%$469.57MN/A-2.933Gap UpABVXABIVAX Société Anonyme2.0154 of 5 stars$7.40+3.2%$38.67+422.5%-33.4%$468.94MN/A0.0061News CoveragePGENPrecigen3.954 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$468.59M$6.22M0.00190 Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Entrada Therapeutics Alternatives Cartesian Therapeutics Alternatives Humacyte Alternatives Arcturus Therapeutics Alternatives SNDL Alternatives KalVista Pharmaceuticals Alternatives ProKidney Alternatives ABIVAX Société Anonyme Alternatives Precigen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TELO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
